Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10342813 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(12 years from now) | |
US10130646 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(12 years from now) |
Drugs and Companies using CALCIUM GLUCONATE ingredient
Market Authorisation Date: 29 October, 2018
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(11 years from now) | |
US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(11 years from now) |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 October, 2015
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6528540 | HQ SPCLT PHARMA | Esmolol formulation |
Jan, 2021
(3 years ago) | |
US6310094 | HQ SPCLT PHARMA | Ready-to-use esmolol solution |
Jan, 2021
(3 years ago) | |
US6528540 (Pediatric) | HQ SPCLT PHARMA | Esmolol formulation |
Jul, 2021
(3 years ago) | |
US6310094 (Pediatric) | HQ SPCLT PHARMA | Ready-to-use esmolol solution |
Jul, 2021
(3 years ago) | |
US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6528540 | HQ SPCLT PHARMA | Esmolol formulation |
Jan, 2021
(3 years ago) | |
US6310094 | HQ SPCLT PHARMA | Ready-to-use esmolol solution |
Jan, 2021
(3 years ago) | |
US6310094 (Pediatric) | HQ SPCLT PHARMA | Ready-to-use esmolol solution |
Jul, 2021
(3 years ago) | |
US6528540 (Pediatric) | HQ SPCLT PHARMA | Esmolol formulation |
Jul, 2021
(3 years ago) | |
US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION